In addition, randomized controlled trials have found that IDeg is associated with significantly lower rates of severe hypoglycemia and nocturnal hypoglycemia than is insulin glargine U-100 in patients with T2D while providing equivalent glycemic control [7–9]. This evidence concerns the gene INS and type 2 diabetes mellitus.